Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of 'Continuous Use' Of Celecoxib Vs. The 'Usual Use' Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-Inflammatory Medication for Control Of Their Pain.

X
Trial Profile

Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of 'Continuous Use' Of Celecoxib Vs. The 'Usual Use' Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-Inflammatory Medication for Control Of Their Pain.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Jun 2012 WOMAC outcomes presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 09 Jun 2012 Disease flare outcomes presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 01 Nov 2011 Results published in The Journal of rheumatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top